Live Vaccine Against Measles, Mumps, and Rubella and the Risk of Hospital Admissions for Nontargeted Infections

Source: Journal of the American Medical Association | Vol:Vol. 311 | Page: 826

By: Sørup, Signe ; Benn, Christine S. ; Poulsen, Anja


Researchers studied 495,987 Danish children born between 1997 and 2006 to determine whether the live measles, mumps, and rubella (MMR) vaccine helped lower rates of hospital admissions for infections. The adjusted incidence rate ratio (IRR) of hospital admissions for any infection was 0.86 for the 456,043 children who followed the recommended vaccination schedule, which called for the inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) at three months, five months, and 12 months and MMR at 15 months. However, the IRR of hospital admissions for infection was 1.62 for the 1,981 children who subsequently received the third dose of DTaP-IPV-Hib after MMR. Researchers calculated a 4.6 percent risk of admission for infection between 16 months and 24 months for those receiving the MMR vaccine on schedule, compared with 5.1 percent for those receiving the MMR vaccine out of sequence. They concluded that receiving the live MMR vaccine as the most recent vaccine, versus inactivated DTap-IPV-Hib, was associated with a lower rate of hospital admissions for infection.

Copyright © 2014 Information, Inc.